Arshi Denton

417 total citations
8 papers, 284 citations indexed

About

Arshi Denton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Arshi Denton has authored 8 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Epidemiology. Recurrent topics in Arshi Denton's work include Gastric Cancer Management and Outcomes (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Advanced Breast Cancer Therapies (1 paper). Arshi Denton is often cited by papers focused on Gastric Cancer Management and Outcomes (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Advanced Breast Cancer Therapies (1 paper). Arshi Denton collaborates with scholars based in United Kingdom and United States. Arshi Denton's co-authors include JaneMaree Maher, Noel W. Clarke, Alastair Forbes, Jervoise Andreyev, Hartmut Kristeleit, Peter Harper, Alistair Ring, Simon Waters, Stephen Johnston and Anthony Antoniou and has published in prestigious journals such as Cochrane Database of Systematic Reviews, Breast Cancer Research and Treatment and Lung Cancer.

In The Last Decade

Arshi Denton

6 papers receiving 268 citations

Peers

Arshi Denton

SURGE

ONCOL

RNMI

PRM

OG

J. Livsey United Kingdom

Richard Ferguson Australia

Heather Schultz United States

Keiko Miyakoda Japan

Tarun Kumar India

Mohamed Tligui France

Pasquale Ialongo Italy

Parashar J. Nanavati United States

Gautum Agarwal United States

M. Katayoon Rezaei United States

J. Livsey United Kingdom

Arshi Denton

170 ×1.3

SURGE

35 ×0.3

ONCOL

56 ×0.7

RNMI

132 ×1.9

PRM

70 ×1.1

OG

Citations per year, relative to Arshi Denton Arshi Denton (= 1×) peers J. Livsey

Countries citing papers authored by Arshi Denton

Since Specialization

Citations

This map shows the geographic impact of Arshi Denton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arshi Denton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arshi Denton more than expected).

Fields of papers citing papers by Arshi Denton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arshi Denton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arshi Denton. The network helps show where Arshi Denton may publish in the future.

Co-authorship network of co-authors of Arshi Denton

This figure shows the co-authorship network connecting the top 25 collaborators of Arshi Denton. A scholar is included among the top collaborators of Arshi Denton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arshi Denton. Arshi Denton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Polychronis, Andreas, Γεώργιος Αντωνίου, Arshi Denton, et al.. (2024). 85 Assessing tolerability and toxicity of adjuvant Osimertinib following tumour resection of early-stage EGFR-mutated non-small cell lung cancer through real-world data. Lung Cancer. 190. 107646–107646.

2.

Afxentiou, Thalia, Andreas Polychronis, Arshi Denton, et al.. (2024). 63 Real-world outcomes of Nivlolumab-Ipilimumab combination therapy in unresectable malignant mesothelioma: Mount Vernon Cancer Centre Experience. Lung Cancer. 190. 107624–107624.

3.

Cui, Wanyuan, Nick Brown, Victoria Brown, et al.. (2022). Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. Lung Cancer. 165. S38–S39. 2 indexed citations

4.

Corr, Alison, et al.. (2021). Small cell rectal cancer: a therapeutic challenge. BMJ Case Reports. 14(10). e244108–e244108. 2 indexed citations

5.

Battisti, Nicolò Matteo Luca, Belinda Kingston, Judy King, et al.. (2019). Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Research and Treatment. 174(3). 731–740. 15 indexed citations

6.

Denton, Arshi & JaneMaree Maher. (2003). Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database of Systematic Reviews. 2015(2). CD003750–CD003750. 89 indexed citations

7.

Denton, Arshi, Jervoise Andreyev, Alastair Forbes, & JaneMaree Maher. (2002). Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database of Systematic Reviews. CD003455–CD003455. 75 indexed citations

8.

Denton, Arshi, Noel W. Clarke, & JaneMaree Maher. (2002). Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database of Systematic Reviews. 2022(1). CD001773–CD001773. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact